TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
TELA Bio (NASDAQ: TELA) announced inducement restricted stock unit grants covering 89,250 shares to 12 newly hired employees, with a grant date of May 5, 2026. The RSUs vest in equal annual installments over four years, subject to continued service through each vesting date.
Positive
- None.
Negative
- None.
News Market Reaction – TELA
In the May 8 session, TELA declined 7.27%, reflecting a notable negative market reaction. Argus tracked a peak move of +12.3% during that session. Argus tracked a trough of -2.8% from its starting point during tracking. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 30 | Board refresh & prelim revenue | Positive | +13.1% | Board refresh and preliminary Q1 2026 revenue above prior guidance. |
| Apr 21 | Earnings date notice | Neutral | -2.6% | Announcement of Q1 2026 earnings release date and conference call logistics. |
| Mar 24 | Q4 & 2025 earnings | Positive | -9.3% | Reported 2025 revenue growth, higher margins, and new credit facility details. |
| Mar 10 | Earnings date notice | Neutral | -7.3% | Set timing and access details for Q4 and full-year 2025 earnings call. |
| Feb 20 | Prior inducement grants | Neutral | +6.8% | Inducement RSUs covering 8,550 shares for three new hires under Rule 5635(c)(4). |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent history shows mixed reactions: positive board and revenue updates saw a 13.07% gain, while detailed earnings in March led to a -9.35% move. Earnings-date announcements often coincided with modest declines, and a prior inducement grant in February saw a 6.77% rise.
Over the last few months, TELA released multiple corporate and financial updates. A March 10-K and March 8-K detailed $80.3M 2025 revenue, improved gross margins, and continued net losses. An 8-K on March 20 highlighted Nasdaq minimum bid-price non-compliance. More recently, board refresh news with preliminary $19.0M Q1 2026 revenue drove a 13.07% gain. A February inducement RSU grant under Nasdaq Rule 5635(c)(4) covered 8,550 shares, similar in structure to today’s announcement.
Key Terms
restricted stock units financial
Nasdaq Rule 5635(c)(4) regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
MALVERN, Pa., May 07, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 89,250 shares of its common stock to 12 newly-hired employees, with a grant date of May 5, 2026 (the "Grant Date"). The restricted stock units were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual's employment compensation and were granted as an inducement material to his or her acceptance of employment with TELA Bio.
The restricted stock units will vest in equal annual installments over four years, subject to each individual's continued service with TELA Bio through the applicable vesting dates.
About TELA Bio, Inc.
TELA Bio, Inc. (NASDAQ: TELA) is a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy. The Company is committed to providing surgeons with advanced, economically effective soft-tissue reconstruction solutions that leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. For more information, visit www.telabio.com.
Caution Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations are forward-looking statements and reflect the current beliefs of TELA Bio's management. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements. These risks and uncertainties are described more fully in the "Risk Factors" section and elsewhere in our filings with the Securities and Exchange Commission and available at www.sec.gov, including in our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Any forward-looking statements that we make in this announcement speak only as of the date of this press release, and TELA Bio assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise after the date of this press release, except as required under applicable law.
Investor Contact
Louisa Smith
ir@telabio.com
